key: cord-0688184-3wh7t7ok
authors: Musoni, L.; Ezzouine, H.; Etouki, O.; Habibou, H.; Nour, M.; ElKhaouri, I.; Charra, B.
title: Covid-19 decompensating epilepsy in the elderly: A case report
date: 2021-07-29
journal: Ann Med Surg (Lond)
DOI: 10.1016/j.amsu.2021.102642
sha: fa651b55cae1099b52a1942f6fae6831c5e6dd27
doc_id: 688184
cord_uid: 3wh7t7ok

The COVID-19 pandemic has had a great impact on chronic diseases, including epilepsy. The imbalance of antiepileptic drugs in case of intercurrent infection with COVID-19 leads to worsening seizures. A 71-year-old man, followed for post-traumatic epilepsy for 30 years, was stabilized with phenobarbital and topiramate. He presented generalized tonic-clonic epileptic seizures without meningitis. He improved well on midazolam combined with the usual treatment before the diagnosis and worsening of the covid-19. The severity of the lung damage led to hypoxia, recurrence of seizures, and poor prognosis. The association between covid-19 and epilepsy remains pejorative despite management. An epileptic seizure should always be considered as a possible manifestation of COVID-19. The article aimed to establish the relationship between covid-19 and the risk of worsening seizures and to demonstrate the severity of the association between covid-19 and epilepsy in elderly patients.

The COVID-19 pandemic has had a great impact on chronic diseases, including epilepsy (1) . Lockdown with difficult access to healthcare facilities is a significant cause of epilepsy decompensation (2) . In addition, the imbalance of the background treatment of the epileptic disease in case of intercurrent infection with COVID-19 was a major cause of worsening seizures, especially in elderly patients. The article aimed to establish the relationship between covid-19 and the risk of worsening seizures and to demonstrate, from a case report, the severity of the association between covid-19 and epilepsy in elderly patients. This manuscript has been reported in line with SCARE's 2020 Criteria (3).

We report a 71-year-old male patient, followed for post-traumatic epilepsy for 30 years. He was stable on dual antiepileptic therapy with phenobarbital and topiramate and was seizure-free for three years. He presented generalized tonic-clonic epileptic seizures without consciousness recovery between seizures despite therapeutic compliance with unquantified fever. On admission, he was unconscious with a GCS of 08/15, reactive and symmetrical pupils, without deficit or localization signs. He was hemodynamically and respiratory stable with apyrexia at 37.3°C. Lumbar puncture showed clear fluid with less than 3 leukocytes, proteinorrachia at 0.61g/L, glycorrachia at 3.74moml/L; glycorrachia/ glycemia ratio at 0.68 with direct test negative and sterile culture. Brain CT scan showed diffuse cortico-subcortical atrophy (Image-1) without other abnormalities. Initial management was mechanical ventilation, sedation with continuous flow midazolam, phenobarbital, and topiramate in usual doses, ceftriaxone meningeal dose. The evolution was marked by clinical and biological improvement and the patient was extubated on day 4. Three days after extubation, he presented a polypnea at 24 cycles per minute with desaturation up to 80% on ambient air, which motivated a RT-PCR of the nasopharyngeal swab that came back positive. A thoracic CT scan showed extensive pulmonary lesions at less than 10% compatible with a viral pneumopathy of the COVID-19 type motivating oxygen therapy and then non-invasive mechanical ventilation. The bioassay noted a disturbing inflammatory balance, including C-reactive protein at 320mg/L, Il 6 at 19.89ng/L, and lymphopenia at 600/mm3 without hydro electrolytic disorders. The COVID-19 drug treatment was added to the anti-epileptic drugs, following the national protocol associating hydroxychloroquine with azithromycin, high-dose vitamin C, zinc, and corticoids. The evolution was marked by the occurrence of iterative partial hemifacial seizures on the 10th day with a worsening of the respiratory condition requiring intubation and assisted ventilation and resumption of sedation with midazolam. A control thoracic CT scan (Image-2) revealed an extension and worsening of the parenchymal lesions estimated at 75% without any notion of pulmonary embolism. The overall evolution was marked by a disappearance of the seizures with, however, a worsening of the respiratory status, refractory hypoxia, and death of the patient on the 14th day of hospitalization.

Covid-19 may cause neurological symptoms while other patients may be asymptomatic. Since neurological manifestations can be the only and first signs of covid-19 (4), it could also break down stable epilepsy through its neurotropic and neuroinvasive abilities described in humans (5) . It could enter the central nervous system by binding to the angiotensin 2 converting enzyme receptor in the oropharynx reaching the olfactory bulb and causing inflammation with possible demyelination (5, 6) . Indeed, neuronal hyperexcitability may be induced by the release of proinflammatory cytokines due to the neurological damage of COVID-19 (6) and may be worsened by difficult access to care (2) . The patient presented epileptic seizures with no obvious causes motivating the consultation, but the recent literature on COVID-19 reports the presence of various neurological manifestations that can be central or peripheral (4, 7) . The resulting apoptosis and neuronal necrosis, particularly localized in the hippocampus, can be exacerbated by these proinflammatory cytokines which play a major role in epileptic pathogenesis. This becomes an additional factor of decompensation in elderly epileptic patients whose acute metabolic disorders, even minimal, electrolyte disorders, hypoxia, and fever can trigger an epileptic seizure (6) . The incidence of COVID-19 infection is higher in patients with epilepsy compared to the general population and particularly in the elderly (8) . In the management of epileptic seizures, we resorted to benzodiazepines based on midazolam continuously and it was recommended in special situations but must be transiently pending the amendment of the triggering factor and the effectiveness of the background treatment introduced (9) . The management of COVID-19 in epileptic patients can be difficult because of possible drug interactions that may lead to organ dysfunction requiring adaptation of antiepileptic drugs (10) . However, the choice of antiepileptic drugs should take into account the type of epilepsy, its etiology, age, sex, comorbidities, the efficacy-tolerance ratio, and its cost. In elderly patients, the use of the least sedating and the easiest-to-use drug should be preferred, especially in low-dose monotherapy, because of the risk of side effects (9).

Elderly epileptic patients are more susceptible to symptomatic COVID-19 with possible decompensation of epilepsy despite therapeutic compliance. In the pandemic situation, an epileptic seizure should always be considered as a possible manifestation of COVID-19, and in its management; the background treatment of epilepsy should be maintained or adapted to the clinical situation of the patient. The association between COVID -19 and epilepsy remains pejorative despite management.

Written informed consent was obtained from the patient's family for publication of this case and accompanying images. A copy of the written consent is available for review by the Editor-in-chief of this journal on request.

Not commissioned, externally peer reviewed.

Epilepsy Care in the Time of COVID-19 Pandemic in Italy: Risk Factors for Seizure Worsening

Seizure control, stress, and access to care during the COVID-19 pandemic in New York City: The patient perspective

The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines

The neurological manifestations of COVID-19: a review article

Central nervous system manifestations of COVID-19: A systematic review

How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms

Epilepsy course during COVID-19 pandemic in three Italian epilepsy centers

Incidence and case fatality rate of COVID-19 in patients with active epilepsy

EMC MAJ I 2020 -Neurologie

Management of COVID-19 in people with epilepsy: drug considerations

Chest CT scan showing frosted glass images Image1: Brain CT scan showing diffuse cortico subcortical atrophy

We would like to thank the chief of the Intensive Care Unit and all the team who participated in the care of the patients for whom we owe all the data.

Authors must obtain written and signed consent to publish a case report from the patient (or, where applicable, the patient's guardian or next of kin) prior to submission. We ask Authors to confirm as part of the submission process that such consent has been obtained, and the manuscript must include a statement to this effect in a consent section at the end of the manuscript, as follows: "Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request".Patients have a right to privacy. Patients' and volunteers' names, initials, or hospital numbers should not be used. Images of patients or volunteers should not be used unless the information is J o u r n a l P r e -p r o o f essential for scientific purposes and explicit permission has been given as part of the consent. If such consent is made subject to any conditions, the Editor in Chief must be made aware of all such conditions. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning and editors should so note.Written informed consent was obtained from the patient's family for publication of this case and accompanying images. A copy of the written consent is available for review by the Editor-in-chief of this journal on request.

Please specify the contribution of each author to the paper, e.g. study concept or design, data collection, data analysis or interpretation, writing the paper, others, who have contributed in other ways should be listed as contributors.Libérat Musoni: designed the study, wrote the protocol and the first draft of the manuscript Hanane Ezzouine: designed the study, wrote the protocol and the first draft of the manuscript Omar Ettouki: designed the study, wrote the protocol and the first draft of the manuscript Habibou Rabiou: managed the analyses, and the correction of the manuscript Mariam Nour: managed the analyses, and the correction of the manuscript Imane Elkhaouri: managed the analyses, and the correction of the manuscript Boubaker charra: reading and correction of the manuscript All authors read and approved the final manuscript.

In accordance with the Declaration of Helsinki 2013, all research involving human participants has to be registered in a publicly accessible database. Please enter the name of the registry and the unique identifying number (UIN) of your study.You can register any type of research at http://www.researchregistry.com to obtain your UIN if you have not already registered. This is mandatory for human studies only. Trials and certain observational research can also be registered elsewhere such as: ClinicalTrials.gov or ISRCTN or numerous other registries.

The Guarantor is the one or more people who accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish

J o u r n a l P r e -p r o o f